These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23741320)

  • 1. Cancer associated E17K mutation causes rapid conformational drift in AKT1 pleckstrin homology (PH) domain.
    Kumar A; Purohit R
    PLoS One; 2013; 8(5):e64364. PubMed ID: 23741320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
    Thirumal Kumar D; Jain N; Evangeline J; Kamaraj B; Siva R; Zayed H; George Priya Doss C
    Comput Biol Med; 2019 Dec; 115():103513. PubMed ID: 31698236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
    Landgraf KE; Pilling C; Falke JJ
    Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
    Carpten JD; Faber AL; Horn C; Donoho GP; Briggs SL; Robbins CM; Hostetter G; Boguslawski S; Moses TY; Savage S; Uhlik M; Lin A; Du J; Qian YW; Zeckner DJ; Tucker-Kellogg G; Touchman J; Patel K; Mousses S; Bittner M; Schevitz R; Lai MH; Blanchard KL; Thomas JE
    Nature; 2007 Jul; 448(7152):439-44. PubMed ID: 17611497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GRP1 PH domain, like the AKT1 PH domain, possesses a sentry glutamate residue essential for specific targeting to plasma membrane PI(3,4,5)P(3).
    Pilling C; Landgraf KE; Falke JJ
    Biochemistry; 2011 Nov; 50(45):9845-56. PubMed ID: 21932773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
    Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
    Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
    Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
    Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
    Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
    Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.
    Cohen Y; Shalmon B; Korach J; Barshack I; Fridman E; Rechavi G
    Gynecol Oncol; 2010 Jan; 116(1):88-91. PubMed ID: 19853286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular mechanism behind protein kinase B natural mutant E17K affecting the allosteric inhibitor sensitivity: a molecular dynamics simulation study.
    Wang Y; Jia R; Tan W
    J Biomol Struct Dyn; 2021 Jun; 39(9):3158-3171. PubMed ID: 32452271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma.
    Zilberman DE; Cohen Y; Amariglio N; Fridman E; Ramon J; Rechavi G
    Cancer Genet Cytogenet; 2009 May; 191(1):34-7. PubMed ID: 19389506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian Cancer.
    Ajjarapu SM; Tiwari A; Taj G; Singh DB; Singh S; Kumar S
    BMC Pharmacol Toxicol; 2021 Nov; 22(1):68. PubMed ID: 34727985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.
    Parikh C; Janakiraman V; Wu WI; Foo CK; Kljavin NM; Chaudhuri S; Stawiski E; Lee B; Lin J; Li H; Lorenzo MN; Yuan W; Guillory J; Jackson M; Rondon J; Franke Y; Bowman KK; Sagolla M; Stinson J; Wu TD; Wu J; Stokoe D; Stern HM; Brandhuber BJ; Lin K; Skelton NJ; Seshagiri S
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19368-73. PubMed ID: 23134728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational identification of significant missense mutations in AKT1 gene.
    Shanthi V; Rajasekaran R; Ramanathan K
    Cell Biochem Biophys; 2014 Nov; 70(2):957-65. PubMed ID: 24809327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
    Malanga D; Scrima M; De Marco C; Fabiani F; De Rosa N; De Gisi S; Malara N; Savino R; Rocco G; Chiappetta G; Franco R; Tirino V; Pirozzi G; Viglietto G
    Cell Cycle; 2008 Mar; 7(5):665-9. PubMed ID: 18256540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.
    Wu WI; Voegtli WC; Sturgis HL; Dizon FP; Vigers GP; Brandhuber BJ
    PLoS One; 2010 Sep; 5(9):e12913. PubMed ID: 20886116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1.
    Deyle KM; Farrow B; Qiao Hee Y; Work J; Wong M; Lai B; Umeda A; Millward SW; Nag A; Das S; Heath JR
    Nat Chem; 2015 May; 7(5):455-62. PubMed ID: 25901825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic.
    Dannemann N; Hart JR; Ueno L; Vogt PK
    Int J Cancer; 2010 Jul; 127(1):239-44. PubMed ID: 19876913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT Inhibition in Solid Tumors With AKT1 Mutations.
    Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
    J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of a highly deleterious mutation E17K in AKT-1 gene: An
    Khan I; Ansari IA
    Biochem Biophys Rep; 2017 Jul; 10():260-266. PubMed ID: 29114575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.